A clinical trailto study the effects of two drugs, Pregabalin and Dulexetine in patients with neuropathic pain due to prolapsed intervertibral disc (PIVD)

A STUDY OF EFFICACY AND SAFETY OF PREGABALIN COMPARE TO DULOXETINE IN NEUROPATHIC PAIN AMONG PATIENTS WITH PROLAPSED INTER VERTEBRAL DISC IN A TEACHING HOSPITAL: - AN OPEN LABEL NON RANDOMISED CONTROL TRIAL.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/06/034453

Enrollment

200

Registered

2021-06-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M512- Other thoracic, thoracolumbar andlumbosacral intervertebral disc displacement

Interventions

Intervention1: Tab Dulexetine: 30mg at bed time for 4 weeks Control Intervention1: Tab Pregabaline: 75 mg b. d. for four weeks.

Eligibility

Inclusion criteria

Inclusion criteria: 18 years and above, all clinically diagnosed cases of neuropathic pain due to PIVD and who will be prescribed either Pregabalin or Duloxetine and fulfill the following criteria a) Patients whose visual analogue scale >4. b) Patients having DN4 questionnaires score >4. c) Leeds assessment of neuropathic symptoms and sign (LANSS) >12

Exclusion criteria

Exclusion criteria: a) Neuropathic pain due to other co-morbidities e.g. (Peripheral Neuropathy, Alcoholic, Cancer). b) Pregnancy and lactation. c) Mental disorder. d) Those who are receiving herbal medicine and homeopathy or any other medicine having pain modulator properties except NSAIDS. e) Those who taken Pregabalin / Gabapentin or Duloxetine prior to the study

Design outcomes

Primary

Measure	Time frame
To compare the efficacy between Pregabalin and Duloxetine in reducing the neuropathic pain due to Prolapsed intervertibral disc(PIVD)Timepoint: After four weeks.	—

Secondary

Measure	Time frame
To assess the adverse events of Pregabalin compare to Duloxetine among the study participantsTimepoint: After four weeks.	—

Countries

India

Contacts

Public ContactDr Satyabrata Nath

Agartala government Medical College

sbnathpmr@gmail.com7629817096

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026